BIOCONJUGATE INSIGHTS

From bench to bedside: translating ADCs into the clinic

From bench to bedside: translating ADCs into the clinic

Managing atypical toxicity profiles and response timelines to optimize dosing strategies for safety and efficacy
Selecting clinical endpoints aligned with new payload mechanisms to demonstrate value
Using biomarker-guided patient selection to improve trial outcomes and success rates
IND-ready analytical packages to expedite submission timelines
Ensuring scalability and scale-up readiness as conjugates advance to late-stage development
Bridging into GMP to meet regulatory standards for clinical trial materials
Leveraging imaging-based early endpoints for clinical trial acceleration

Linker design and payload innovation

Linker design and payload innovation

Engineering hydrophilic polymers or PEGylated linkers to improve aggregation and clearance issues while improving circulation time
Developing extracellular or environment-responsive cleavable linkers to improve targeted payload release
Explore dual payload integration and their synergistic release profiles to achieve synergistic therapeutic effects
Incorporating PROTAC-based payloads for improved targeted protein degradation
Utilizing AI tools to predict linker aggregation and cleavage performance
Backbone engineering to fine-tune payload exposure
- Investigating RNA payload conjugation for gene modulation and silencing

Manufacturing strategies to move the bioconjugate field forward

Manufacturing strategies to move the bioconjugate field forward

Controlling DAR variability in conjugation techniques to improve consistency
Applying enzymatic conjugation methods to achieve uniformity and reduce heterogeneity
Incorporating hydrophobic masking strategies to reduce aggregation and improve solubility
Translating academic ‘ideas’ into scalable, robust manufacturing processes suitable for industry
Considering conjugated vaccine manufacturing to expand bioconjugate applications beyond oncology therapeutics
Applying QbD principles and early regulatory engagement to streamline approvals for novel modalities
Considering diagnostic bioconjugates alongside therapeutic modalities to support platform scalability

Tackling site-specificity in ADCs

Tackling site-specificity in ADCs

Implementing site-specific approaches to reduce DAR heterogeneity and improve conjugate predictability
Scaling enzymatic conjugation techniques without compromising precision to enable viability
- Balancing chemical and enzymatic approaches to achieve both stability and targeted placement of payloads
Using AI modeling to predict optimal conjugation sites and improve efficiency
Validating conjugation sites functionally to confirm that modifications do not compromise activity
Predicting immunogenicity and clearance risks from conjugation location
Standardizing protocols for cross-platform comparability and regulatory alignment

Building the ideal bioconjugate scaffold through antibody discovery and engineering

Building the ideal bioconjugate scaffold through antibody discovery and engineering

Engineering Fc regions for enhanced half-life and reduced immunogenicity
AI-driven epitope mapping for novel antibody scaffolds
Incorporation of engineered cysteine or unnatural amino acids for site-specific conjugation
Bi- and multi-specific antibody engineering to expand targeting breadth
Tailoring affinity and avidity to match payload characteristics
Leveraging phage display and synthetic libraries for antibody candidate discovery
Humanization strategies to broaden patient compatibility

Enabling controlled and sustained release

Enabling controlled and sustained release

Balancing payload stability in circulation with rapid activation at the target site to optimize therapeutic windows
Advancing click-cleavable and redox-sensitive linker technologies for precision release
Designing dual-trigger mechanisms (e.g., pH and enzyme) for selective payload delivery to refine selectivity
Assessing real-time in vitro and in vivo assays to model linker cleavage under physiological conditions
- Managing immunogenicity risks with cleavable vs non-cleavable linker designs
Controlled release for chronic diseases requiring long-term, low-dose exposure
Exploring multimodal release platforms to achieve spatial and temporal control of payload delivery

Beyond antibodies: the new frontiers of bioconjugation

Beyond antibodies: the new frontiers of bioconjugation

Enhancing intracellular delivery of oligonucleotides and peptides through innovative carries such as nanoparticles, fusogenic peptides, and cell-penetrating tags
Engineering backbone modifications (e.g., phosphorothioates) to stabilize oligonucleotides and reduce immune response
Reducing immunogenicity in oligos via sequence engineering and immune profiling
Developing peptide conjugates with improved stability via cyclization and stapling techniques
Designing modular linkers to enable flexible payload pairing across modalities
Addressing synthesis and purification complexity in mixed-modality conjugates
Creating targeted peptide-drug conjugates to achieve tissue-specific delivery with minimal toxicity

Measuring what matters: analytics for bioconjugate characterization

Measuring what matters: analytics for bioconjugate characterization

Addressing inconsistent DAR and its PK/PD implications to assess efficacy
Integrating multi-attribute methods for comprehensive conjugate characterization
Pinpointing off-target conjugation with LC-MS mapping to improve safety profiles
Monitoring aggregation and degradation in real-time with SEC, light scattering, and LC-MS tools to ensure conjugate stability
Implementing cell-based potency assays to confirm functional consistency
Integrating radioconjugates as part of analytical workflows for functional readouts to explore diagnostics and theranostic opportunities

Innovations in targeting and precision delivery

Innovations in targeting and precision delivery

Navigating tumor heterogeneity and ensuring sufficient antigen expression across patient populations
Enhancing binding specificity to minimize off-target effects in healthy tissues
Leveraging AI/ML for antigen select ion and target validation
Fine-tuning internalization kinetics to optimize payload release timing
Incorporating non-traditional moie-ties such as small molecule ligands or aptamers for intracellular targets
Utilizing targeted nanoparticles and modular conjugation systems for receptor-mediated endocytosis to broaden delivery options

Overcoming ADC manufacturing bottlenecks

Overcoming ADC manufacturing bottlenecks

Achieving batch-to-batch consistency in DAR to ensure reliable ADC performance
Avoiding aggregation during conjugat ion and purification to maintain conjugate quality
Addressing limitations of chromatography in large-scale manufacturing for improved scalability
Managing supply chain fragility for payloads, linkers, and antibodies to ensure uninterrupted production
Utilizing advanced bioassays for predictive quality and functional equivalence in early development

Future directions in bioconjugation: designing next-generation therapies

Future directions in bioconjugation: designing next-generation therapies

Expanding applications beyond oncology to include autoimmune, infectious, and neurological diseases
Designing conditionally active constructs to minimize systemic exposure and enhance safety
Developing bi- and multi-specific scaffolds to improve targeting breadth and therapeutic potential
Creating long-circulating conjugates with reduced clearance for chronic conditions
Establishing new regulatory endpoints tailored to non-oncology indications
Incorporating companion diagnostics and theranostics to guide treatment and validate targets

}